X

Trial Profile

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 24 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Acute myeloid leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
Focus Adverse reactions

Most Recent Events

07 May 2020 Planned End Date changed from 1 Feb 2020 to 1 Feb 2029.
07 May 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Feb 2023.
04 Dec 2018 Results (n=11) assessing safety of pembrolizumab in relapsed patients following allogeneic hematopoietic cell transplantation, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com